1. Introduction {#sec1}
===============

1.1. Scope of review {#sec1.1}
--------------------

Stress-related substance use poses a critical challenge for treating all substance use disorders (SUDs), yet this scientific field is at an early investigational stage. Candidate therapies for attenuating stress-potentiated drug-seeking/use include medications, neuro-stimulation, cognitive-behavioral, exercise/physical activity, and other approaches. Due to that panoramic breadth, this selective review focuses on neuropharmacological strategies grounded in preclinical and clinical evidence that offer translational promise for reducing stress-induced seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids. This review does not discuss effects of medications on attenuating drug-abstinence signs/symptoms (which are stressful); although withdrawal effects can lead to drug seeking, that outcome is not inevitable, mostly relates to physical dependence on specific substances, and retaining that topic would greatly lengthen this review. In short, this restricted scope highlights neurochemical mechanisms for reducing stress-induced seeking/self-administration for the most prevalent abused substances. Literature gaps are identified as a means to advance this field of inquiry.

1.2. Neurobehavioral mechanisms underlying drug-seeking/self-administration {#sec1.2}
---------------------------------------------------------------------------

Mechanisms that link stress reactivity to psychoactive substance use/abuse are complex and incompletely understood. Stressors modulate the neurobehavioral effects of abused substances in stressor-, procedure- and drug-class-specific ways, but also activate some common brain pathways ([@bib14]; [@bib233]). Excellent reviews at a more granular level than this translational review indicate numerous neurochemical systems modulate stress-induced substance-seeking/use including noradrenaline (NA), hypothalamic-pituitary-adrenal (HPA) axis including corticotrophin-releasing factor (CRF) and glucocorticoids, opioid, endocannabinoid (eCB), serotonin (5-HT), orexin/hypocretin, dopamine (DA), glutamate, and γ-amino-butyric acid (GABA) ([@bib47]; [@bib97]; [@bib148]; [@bib161]; [@bib193]; [@bib239]; [@bib289]; [@bib352], [@bib350]; [@bib360]; [@bib362]; [@bib410]), and other systems that are less well studied (see section [2.10](#sec2.10){ref-type="sec"}). Due to this "neuro-symphony of stress" ([@bib174]), it is only feasible to study a limited number of mechanisms at the same time. When relevant, I mention research that has examined pairwise interactions of transmitter systems.

A *motivational systems model* ([Fig. 1](#fig1){ref-type="fig"}), based on affective neuroscience theories ([@bib7]; [@bib24]; [@bib85]; [@bib91]) suggests that three empirically separable dimensions may underlie stress-induced drug seeking/use, being greatest at the nexus of negative-hedonic or dysphoric (avoidance-punishment), high-arousal (activation), and low-control (disinhibition) states. Based on research in the *systems biology of addiction* ([@bib18]; [@bib47]; [@bib162]; [@bib192]; [@bib352]; [@bib360]; [@bib372]; [@bib424]; [@bib450]), this review adopts the approach that stress-related drug-seeking/use is a function of dysregulated neural (particularly limbic) systems underlying these affective/motivational dimensions. Throughout this review, I link candidate anti-stress pharmacological approaches to these motivational dimensions (to the extent that current evidence allows).Fig. 1Motivational Systems: Stress-induced substance use behaviors are a function of three motivational dimensions: hedonic valence (approach/avoidance), arousal/activation, and self-control (inhibition/disinhibition). Cone depicts the motivational sector (negative hedonic, high activation, and disinhibition) in which stressors are predicted to amplify drug seeking.Fig. 1

1.3. Experimental models of stress-induced drug-seeking/use {#sec1.3}
-----------------------------------------------------------

Experimental approaches to studying stress-related drug-seeking/use can be classified with regard to: (a) type of stressor, e.g., physical, environmental, and pharmacological, (b) stage in the behavioral cycle of addiction (initiation, progression, maintenance, relapse), and (c) drug-seeking outcome measure (e.g., operant responding for drug, conditioned place preference). This literature review focuses on models of *maintenance and relapse stages*, which more closely translate to individuals presenting for SUD treatment (who have already initiated and progressed). Most studies with laboratory animals to date have measured reinstatement of operant responding for drug as the outcome measure; fewer studies have measured conditioned place preference (CPP) but these are included in this review for comprehensiveness. The CPP model has limitations, particularly because drug is experimenter-administered and drug exposure is minimal.

As summarized in [Table 1](#tbl1){ref-type="table"}, drug seeking/consumption is enhanced by a wide range of stressors including: social factors (defeat, isolation), physical factors (restraint, cold swim, food deprivation, footshock), and pharmacological probes (e.g., *α*2-adrenoceptor antagonist yohimbine \[section [2.1](#sec2.1){ref-type="sec"}\], *kappa*-opioid agonist, and neuropeptides \[sections [2.10](#sec2.10){ref-type="sec"}, [2.2.1](#sec2.2.1){ref-type="sec"}, [2.7](#sec2.7){ref-type="sec"}\]). Each stressor type has strengths and weaknesses, and translation of these models to clinical treatment is limited by several moderating factors, briefly discussed next.Table 1Studies demonstrating a significant direct effect of stressor on reinstatement of (or increase in) seeking behavior, by type of abused substance.Table 1Stress MethodNicotineAlcoholCocaineOpioid**Chemical stressors**Yohimbine[@bib84]; [@bib109]; [@bib145]; [@bib150]; [@bib455]; [@bib436][@bib20]; [@bib21]; [@bib22]; [@bib35], [@bib34]; [@bib76]; [@bib78], [@bib79], [@bib77]; [@bib122], [@bib123]; [@bib126]; [@bib133]; [@bib152]; [@bib185]; [@bib217], [@bib212], [@bib215], [@bib210]; [@bib243]; [@bib277]; [@bib305], [@bib304]; [@bib314]; [@bib319]; [@bib324], [@bib325]; [@bib354]; [@bib359], [@bib358]; [@bib379], [@bib380], [@bib378][@bib3]; [@bib13]; [@bib49]; [@bib69], [@bib71], [@bib70]; [@bib86]; [@bib111]; [@bib110]; [@bib116]; [@bib133]; [@bib221]; [@bib204]; [@bib240],[a](#tbl1fna){ref-type="table-fn"}; [@bib300]; [@bib324]; [@bib331]; [@bib332]; [@bib333]; [@bib429]; [@bib430]; [@bib446][@bib87]; [@bib141][b](#tbl1fnb){ref-type="table-fn"}; [@bib381]; [@bib449]Noradrenaline[@bib50], [@bib49]CRF[@bib216][@bib37], [@bib38]; [@bib50]; [@bib55]; [@bib136]; [@bib203]; [@bib238][@bib343]Caffeine[@bib300]; [@bib386]Kappa-agonist[@bib145][@bib122]; [@bib211][@bib10],[a](#tbl1fna){ref-type="table-fn"}, [@bib11],[a](#tbl1fna){ref-type="table-fn"}; [@bib209],[a](#tbl1fna){ref-type="table-fn"}; [@bib299]; [@bib254],[a](#tbl1fna){ref-type="table-fn"}; [@bib398]Orexin-1[@bib290][@bib43]; [@bib157][@bib157]Neuropeptide S[@bib61][@bib180]; [@bib281]**Non-chemical stressors**Intermittent electric footshock[@bib54]; [@bib53], [@bib52]; [@bib290]; [@bib39]; [@bib451][@bib80]; [@bib88]; [@bib99], [@bib100]; [@bib156]; [@bib220], [@bib219], [@bib218], [@bib216], [@bib217], [@bib213]; [@bib231]; [@bib245]; [@bib322]; [@bib356]; [@bib445][@bib4]; [@bib29], [@bib30]; [@bib104], [@bib105], [@bib103]; [@bib136]; [@bib204], [@bib203]; [@bib241]; [@bib238], [@bib240],[a](#tbl1fna){ref-type="table-fn"}; [@bib245]; [@bib246]; [@bib299]; [@bib413]; [@bib420], [@bib421][@bib205]; [@bib294],[a](#tbl1fna){ref-type="table-fn"}; [@bib345], [@bib346], [@bib344]; [@bib347], [@bib348], [@bib349]; [@bib352], [@bib353]; [@bib423],[a](#tbl1fna){ref-type="table-fn"}; [@bib447], [@bib448]Social defeat[@bib124]; [@bib266]; [@bib307][@bib209],[a](#tbl1fna){ref-type="table-fn"}; [@bib242][@bib303],[a](#tbl1fna){ref-type="table-fn"}Social isolation[@bib44][@bib8]; [@bib44]Physical restraint[@bib416][@bib394][@bib261],[a](#tbl1fna){ref-type="table-fn"}; [@bib303],[a](#tbl1fna){ref-type="table-fn"}Forced swim[@bib171],[a](#tbl1fna){ref-type="table-fn"}[@bib62]; [@bib82]; [@bib138]; [@bib255],[a](#tbl1fna){ref-type="table-fn"}; [@bib260],[a](#tbl1fna){ref-type="table-fn"}; [@bib283]; [@bib291]; [@bib327]; [@bib414],[a](#tbl1fna){ref-type="table-fn"}[@bib182],[a](#tbl1fna){ref-type="table-fn"}; [@bib442]Food deprivation[@bib65]; [@bib72][@bib337]; [@bib352], [@bib351]; [@bib392][^1][^2]

1.4. Translation of experimental models to clinical application: moderator variables {#sec1.4}
------------------------------------------------------------------------------------

Experimental models of stress-related drug seeking/use have not routinely included clinically-relevant factors that might mediate/moderate the efficacy of anti-stress therapeutic agents. Next, I briefly discuss selected factors worthy of investigation in developing anti-stress pharmacotherapies in these models. Detailed analysis of these factors exceeds the scope of this review, but the purpose is to prime the reader to consider these factors in the context of the discussion that follows in section [2](#sec2){ref-type="sec"}.

### 1.4.1. History of substance exposure/use {#sec1.4.1}

The extent to which acute stressors augment the reinforcing effects of psychoactive substances may partly depend on the subject\'s history of substance exposure (e.g., *in utero*) or use (i.e., voluntary intake). Chronic and/or escalating substance intake has been shown to produce stress-like responses that, in turn, sensitize animals -- via CRF, glucocorticoid, and glutamatergic mechanisms -- to acute stress-potentiation of the reinforcing effects of cocaine ([@bib4]; [@bib136]; [@bib238]; [@bib371]) and alcohol ([@bib231]; [@bib356]). These data suggest that agents capable of desensitizing these neurochemical systems could be therapeutically useful, especially for subjects with extensive chronic exposure or high levels of tolerance/dependence.

### 1.4.2. Environmental factors {#sec1.4.2}

Research into effects of stressors on drug-motivated behavior has not adequately investigated the environmental context, particularly non-drug choice alternatives. Higher magnitude or probability of non-drug positive reinforcers in the environment during stress-exposure may bias animals away from habitual drug seeking, i.e., serve a stress-protective function. This phenomenon has been modeled in rats using environmental enrichment ([@bib69]). Future studies should examine whether anti-stress pharmacotherapies are more effective in combination with non-drug positive reinforcers. In contrast, economic insecurities among humans (i.e., dearth of positive reinforcement in a person\'s environment) are chronic stressors that contribute to substance use. Furthermore, magnitude and/or probability of punishers in the subject\'s environment may play an important role in modulating stress-induced drug seeking, although this has rarely been investigated. For instance, early social isolation of rats enhances cocaine motivation, but isolation did not affect extinction or stress-reinstatement of cocaine seeking ([@bib22]). Future studies should investigate whether drug intake that is suppressed by punishment (cf. [@bib285]) is more easily reinstated by stress than drug intake that is suppressed by non-drug positive reinforcers, and whether other factors such as drug history moderate these effects (see [@bib365]).

### 1.4.3. Sleep loss {#sec1.4.3}

Sleep loss (and/or circadian disruption) is a biological stressor but has rarely been investigated in studies of drug seeking/self-administration. This is noteworthy because insomnia is a predictor of relapse to substance abuse ([@bib312]; [@bib181]). Also, sleep loss causes hyperalgesia ([@bib9]; [@bib311]; [@bib401]) that, in turn, may increase misuse of opioids and other substances ([@bib101]; [@bib164]; [@bib415]). Recognizing the role of insomnia as a stressor leads to the idea of treating insomnia as one cause of substance use. Non-addictive sleep-promoting agents might be useful in this regard (see section [2.7](#sec2.7){ref-type="sec"}).

### 1.4.4. Chronic pain {#sec1.4.4}

Stress can increase nociceptive signaling and contribute to chronic pain states ([@bib129]; [@bib169]; [@bib172]; [@bib175]). This overlap is important because it suggests (1) stress-exposure could cross-sensitize subjects -- presumably via shared neurobiological pathways -- to drug seeking, and (2) therapeutics used to attenuate stress-reactivity could have dual actions on analgesia and drug seeking/use. On the other hand, it is well established that stress exposure can sometimes produce analgesia ([@bib57]; [@bib282]). Thus, parametric studies are needed to examine basic interactions between (acute and chronic) stressors and (acute and chronic) nociceptive stimulation, and to translate this knowledge toward the development of therapeutic approaches that could potentially address both conditions.

### 1.4.5. Chronic stress and mental health conditions {#sec1.4.5}

Early-life or chronic stress as well as psychiatric conditions (e.g., anxiety, depression) are highly prevalent among individuals with SUDs and may increase risk of relapse to substance use especially under stressful conditions ([@bib75]; [@bib228]). Experimental animal models have only infrequently created such a behavioral history (e.g., repeatedly exposing animals to anxiety-provoking or helplessness-provoking conditions) or exposed adolescent animals to the biological stressor corticosterone ([@bib10]; [@bib34]) to determine its effects on stress-induced drug seeking/use. Further systematic research would be valuable for understanding a complex yet important set of clinically relevant influences.

### 1.4.6. Trait factors {#sec1.4.6}

Impulsivity is an example of one trait variable that may influence stress-induced drug seeking behavior; furthermore, this trait maps onto a key motivational dimension, disinhibition/control, proposed in this review ([Fig. 1](#fig1){ref-type="fig"}). Specifically, high trait impulsivity (associated with less prefrontal cortical inhibitory control) could, in the presence of a stressor, result in less resistance to drugs and related cues, making the individual more prone to substance use. We have found that the relationship between trait impulsivity on current mood state (e.g., Beck Depression Inventory scores) is mediated by effects of cumulative adverse drug-use consequences for both cocaine and heroin users ([@bib230]; [@bib301]). Other inter-related trait variables such as anxiety sensitivity ([@bib222]), distress tolerance ([@bib48]), emotion regulation ([@bib273]), and resilience or coping ability ([@bib32]; [@bib168]) are stress-mediator/moderator variables that are not routinely assessed in human studies, but these might potentially predict drug abstinence during addiction treatment ([@bib383]).

### 1.4.7. Biological sex {#sec1.4.7}

Chronic manipulation of HPA axis (CORT) during adolescence increases sensitivity to YOH-induced alcohol seeking in female more than male adult rats ([@bib34]). Neonatal isolation stress increased cocaine seeking behavior in adult rats, however, effects did not differ for males and females ([@bib234]). Some effects of acute stressors on relapse-like behavior are sex-dependent, with females typically more sensitive especially during high-estradiol levels ([@bib13]; [@bib23]; [@bib68]; [@bib110]; [@bib386]; [@bib409]) although not all studies observe clear sex differences in stress-induced drug seeking ([@bib55]; [@bib446]; also, see reviews by [@bib31]; [@bib39]; [@bib119]; [@bib166]). Consistent with current NIH policy, studies should be adequately powered to detect sex differences in stress-induced drug seeking/use as well as candidate pharmacotherapies that may attenuate these effects.

### 1.4.8. Neurotransmission-related genetic factors {#sec1.4.8}

Few studies have addressed the role of genetic variation in stress-related substance use and relapse, in contrast to genetic association studies of initial addiction vulnerability. We reported that, in heroin-dependent volunteers undergoing buprenorphine dose tapering with an abstinence incentive, variations in genes encoding the *kappa*-receptor (*OPRK1* rs3802281; [@bib144]) and glucocorticoid receptor (*NR3C1* rs6877893; [@bib139]) predicted opioid relapse potential. Variation in *OPRK1* rs6989250 is also associated with risk of cocaine relapse ([@bib438]). Although CRH-binding protein (*CRHBP*) genotype variation moderated the association between stress-induced negative affect and negative consequences of alcohol intake in heavy-drinking subjects ([@bib388]), effects of this genotype on stress-induced drinking were not studied. Nonetheless, CRF is a promising target, as *CRHR1* knockout animals are less sensitive to stress-induced alcohol intake ([@bib156]; [@bib266]; [@bib283]). CRF-R1 knockdown mice are also less sensitive to stress-reinstatement of cocaine seeking ([@bib72]).

2. Neuropharmacological targets {#sec2}
===============================

This section reviews evidence from studies related to various neurochemical systems that offer anti-stress therapeutic potential. To promote translational studies, each section indicates positron emission tomography (PET) imaging radiotracers that could be used to investigate proof-of-targeting in future prospective studies.

2.1. Noradrenergic system {#sec2.1}
-------------------------

The NA system has been the most commonly studied neurochemical domain for stress-related substance use, alone or in combination with other systems (see below). Discontinuation of chronic exposure to nicotine ([@bib52]; [@bib369]), alcohol ([@bib270]), cocaine ([@bib252]; [@bib370]), and opioids ([@bib237]; [@bib400]) is a functional stressor associated with increased NA neurotransmission. It has been hypothesized that elevated NA release in the extended amygdala, and altered DA-mediated plasticity in the ventral tegmental area (VTA), alter hedonic processing of drug-related stimuli and are common substrates in withdrawal-associated relapse to drug seeking ([@bib18]; [@bib106]; [@bib115]; [@bib364]; [@bib427]).

Yohimbine (YOH) is an α~2~-adrenoceptor antagonist that increases NA neurotransmission by blocking feedback at presynaptic autoreceptors ([@bib95]; [@bib131]) and has become an important tool for investigating stress-related drug seeking/use. YOH-mediated increases in NA release and synaptic levels regulate HPA axis activity ([@bib14]; [@bib26]; [@bib149]; [@bib224]; [@bib366]), as well as 5-HT and DA neurotransmission ([@bib45]; [@bib74]; [@bib165]; [@bib250]; [@bib251]; [@bib264]; [@bib267]; [@bib296]; [@bib367], [@bib368]; [@bib432]). In a PET neuroimaging study of rhesus monkeys, YOH increased \[^11^C\]-flumazenil binding potential ([@bib248]) indicating YOH actions at GABA-A receptors that might correlate with its anxiogenic (negative-hedonic, arousing) and/or disinhibiting motivational effects ([Fig. 1](#fig1){ref-type="fig"}).

YOH has been used extensively as an experimental stressor in animal and human laboratory models. It produces anxiogenic effects in animals, healthy subjects, patients with panic disorder and opioid use disorder, which can be blocked by the α2-adrenoceptor agonist clonidine ([@bib6]; [@bib46]; [@bib59]; [@bib66], [@bib67]; [@bib151]; [@bib249]; [@bib284]; [@bib377]). These anxiogenic effects are presumed to mediate the effects of YOH on the reinforcing effects of drugs and drug-related stimuli. Reviews have concluded that YOH is a reliable and potent inducer of drug seeking with translational value ([@bib42]; [@bib113]; [@bib338]; [@bib342]). On the other hand, [@bib73] found that the effect of YOH on food-reinforced operant behavior may partly depend on factors unrelated to stress-induction; namely, YOH did not induce conditioned place aversion, YOH increased responding independent of the rat\'s history of contingent self-administration of food reward, and YOH increased medial prefrontal cortex (but not nucleus accumbens) dopamine levels. As a result, Chen et al. proposed that YOH may invigorate responding for cues that possess weaker rewarding effects in rodents (also see Box 2 in [@bib239]). Given the extensive use of YOH in experimental stress studies, such findings warrant caution in relying only on YOH as an experimental model, yet encourage further investigation to determine the precise conditions under which YOH exerts its response-enhancing effects. For instance, YOH effects could differ for food vs. drug reinforcers, for paradigms involving drug-paired cues, for single-operant vs. choice scenarios, the subject\'s behavioral history, or other methodological factors.

In animal studies, YOH administration delays extinction of cocaine seeking ([@bib204]) and -- as summarized in [Table 1](#tbl1){ref-type="table"} -- YOH robustly reinstates previously extinguished responding for nicotine, alcohol, cocaine, and opioids. Reinstatement of alcohol seeking by YOH (previously established to be a 5-HT1A partial agonist; [@bib264]; [@bib432]) was blocked not only by the α2 agonist clonidine but also by a selective 5-HT-1A antagonist (WAY-100,635), suggesting an important role for 5-HT in mediating YOH-induced alcohol seeking ([@bib212]; see section [2.3](#sec2.3){ref-type="sec"}). Although YOH did not increase heroin seeking in opioid-dependent rats ([@bib265]), our group was the first to find that YOH increased drug seeking in humans, i.e., the stressor increased opioid-maintained responding in a sample of buprenorphine-maintained heroin-dependent human subjects ([@bib141]) and we recently extended this to cigarette puff-maintained responding in tobacco users ([@bib436]). Tests of YOH to reinstate Δ^9−^THC- responding have not been reported (due to limitations of animal models in demonstrating reinforcing effects of Δ^9^-THC), although chronic Δ^9−^THC exposure during adolescence augmented YOH reinstatement of heroin seeking ([@bib381]).

Furthermore, YOH augments cue-induced reinstatement for nicotine ([@bib84]), heroin ([@bib27]) and cocaine ([@bib56]; [@bib111]; [@bib116]) in animals, and enhances cocaine cue-reactivity in cocaine users ([@bib269]), suggesting this primarily NA stressor can enhance the conditioned reinforcing properties of drug cues to elevate relapse risk. Moreover, across animal and human studies ([@bib1]; [@bib28]; [@bib235]; [@bib321]; [@bib328]; [@bib385]; [@bib387]), YOH and other α2-antagonists increase impulsive responding (i.e., decrease self-control; see [Fig. 1](#fig1){ref-type="fig"}), suggesting another mechanism by which YOH could increase substance use (see [Table 2](#tbl2){ref-type="table"}). Interestingly, NA binding to α2 receptors in prefrontal cortex regulates attentional set, response inhibition and behavioral flexibility ([@bib15]; [@bib17]; [@bib89]; [@bib297]; [@bib310]). YOH also causes perseverative responding ([@bib58]), which predicts that YOH should promote drug-maintained responding particularly habitual substance use.Table 2Candidate therapeutic targets, neuropharmacological agents, and related motivational mechanisms for attenuating stress-induced drug seeking/self-administration.Table 2Stress-motivational dimension[a](#tbl2fna){ref-type="table-fn"}SubstanceCNS TargetExamplesDysphoriaArousalDisinhibitionNicotineAlcoholCocaineOpioidsα2-adrenergic agonistClonidine, lofexidine, guanfacine?++[@bib253][c](#tbl2fnc){ref-type="table-fn"}; [@bib439][@bib217], [@bib215][@bib103]; [@bib221][@bib197][c](#tbl2fnc){ref-type="table-fn"}; [@bib344]α1-adrenergic antagonistPrazosin, doxazosin++[@bib123]; [@bib153][c](#tbl2fnc){ref-type="table-fn"}; [@bib215]; [@bib307]; [@bib428][c](#tbl2fnc){ref-type="table-fn"}β-adrenergic antagonistPropanolol+[@bib240],[b](#tbl2fnb){ref-type="table-fn"}CRF-1 antagonistAntalarmin++[@bib53]; [@bib290][@bib218]; [@bib243][@bib341]; [@bib260],[b](#tbl2fnb){ref-type="table-fn"}[@bib341]Glucocorticoid antagonistMifepristone+[@bib358]; [@bib407][c](#tbl2fnc){ref-type="table-fn"}[@bib182],[b](#tbl2fnb){ref-type="table-fn"}*Kappa*-opioid antagonistNor-BNI, CERC-501, Arodyn++?[@bib145]; [@bib171],[b](#tbl2fnb){ref-type="table-fn"}[@bib94]; [@bib122]; [@bib211]; [@bib313]; [@bib322]; [@bib373],[b](#tbl2fnb){ref-type="table-fn"}[@bib11],[b](#tbl2fnb){ref-type="table-fn"}; [@bib29], [@bib30]; [@bib62],[b](#tbl2fnb){ref-type="table-fn"}; [@bib138]; [@bib299][@bib337]; [@bib449]*Delta*-opioid antagonistSoRI-9409+?[@bib277]Nociceptin antagonistLY2940094++?[@bib314]eCB (anandamide) enhancerURB597, Cannabidiol++?[@bib133][@bib71]; [@bib154]; [@bib133]5-HT-3 antagonistOndansetron, tropisetron+??[@bib214]GABA promotersPregabalin, tiagabine+?/--[@bib380][@bib86]GABA-B agonistBaclofen?+?[@bib430][@bib261],[b](#tbl2fnb){ref-type="table-fn"}mGluR2/3 agonistLY379268+??[@bib356]; [@bib445][@bib246]mGluR5 antagonistMTEP, Fenobam+[@bib356]; [@bib445][@bib246]Orexin-1 antagonistSuvorexant, SB-334867++?[@bib290][@bib61]; [@bib305]; [@bib395][@bib43]; [@bib180]; [@bib281]; [@bib331]; [@bib421][@bib294],[b](#tbl2fnb){ref-type="table-fn"}Oxytocin agonistCarbetocin+?+[@bib442]Vasopressin 1b agonistABT-436++?[@bib447], [@bib448]NPS antagonistRTI-118++[@bib332]NK-1 antagonistAprepitant, L822429??[@bib326], [@bib324], [@bib325][@bib324]Relaxin-3/RXFP3 antagonistR3(B1-22)R, R3(BΔ23-27)R/I5++[@bib319]; [@bib416]PPAR-γ agonistPioglitazone?[@bib87]α3β4 nAChR partial agonistAT-1001[@bib440][@bib77][^3][^4][^5]

The foregoing data suggest agents that reduce NA neurotransmission are first-line candidates as anti-stress medications for at least some SUDs; this proposition has been tested in animal studies. As indicated in [Table 2](#tbl2){ref-type="table"}, the α2-agonists clonidine, lofexidine and guanfacine block stress-reinstated responding for nicotine, alcohol, heroin, cocaine, and heroin/cocaine "speedball" ([@bib163]) at doses that blocked footshock-induced NA release in prefrontal cortex and amygdala. We recently proposed ([@bib436]) that the occupancy ratio of NA receptors (higher-affinity α2-receptors vs. lower-affinity α1-and β-receptors) may underlie stress-induced drug use. Specifically, we hypothesized that during acute stress-exposure, NA released into the synapse may exceed capacity of higher-affinity α2 receptors, possibly leading to spillover binding at lower-affinity α1-and β-receptors; and, in turn, this altered receptor occupancy ratio could potentiate drug seeking. If this theory were confirmed, it could suggest that α1-and β-receptor antagonists may also attenuate drug seeking, especially at higher stress intensities (when NA transmission is greatest). In fact, the α1 antagonists, prazosin and doxazosin, and the α2 agonist guanfacine blocked several types of stress-reinstatement of alcohol-seeking in rodents ([@bib123]; [@bib215]; [@bib307]), as well as YOH-induced motoric impulsivity ([@bib1]). Stress-reinstatement of cocaine seeking is attenuated by the β-receptor antagonist propranolol ([@bib240]) and the NA synthesis inhibitor nepicastat ([@bib333]). However, when injected directly into the amygdala central nucleus, the α1-antagonist prazosin and the β1/2-antagonist propanolol did not attenuate footshock-reinstatement of nicotine seeking, whereas the α2 agonist clonidine did ([@bib439]), highlighting different effects of site-specific versus systemic drug administration across studies. One study found a double dissociation in NA receptor subtypes mediating rewarding and somatic withdrawal effects during mecamylamine-precipitated nicotine withdrawal: only prazosin attenuated brain reward threshold deficits during nicotine withdrawal, whereas only clonidine and propanolol attenuated somatic signs ([@bib52]), suggesting that these NA agents address different motivational mechanisms.

In clinical practice, α2-receptor agonists are typically used as antihypertensive agents and for improving cognitive control in attention-deficit/hyperactivity disorder. Clonidine is a second-line treatment for smoking cessation ([@bib132]) and guanfacine exhibited a promising signal in a pilot-test as a anti-stress/cognitive-control agent in tobacco smokers ([@bib253]). Regarding cannabis use disorder, one study found that lofexidine reduced marijuana relapse-like behavior in a human laboratory model ([@bib155]) but was not generally effective, when combined with oral THC, for reducing outpatient cannabis use ([@bib226]). For cocaine use disorder, during early cocaine abstinence, guanfacine attenuated stress reactivity and craving ([@bib118]) and enhanced inhibitory control ([@bib120]), which might treat dysphoric and impaired self-control dimensions in the drug-motivational space ([Fig. 1](#fig1){ref-type="fig"}). Another study found guanfacine did not attenuate stress responses, prompting the authors to question its value for cocaine use disorder ([@bib268]). Furthermore, these human studies focused on drug craving rather than drug seeking/use, which may limit their clinical utility. Another caveat is that a study in rhesus monkeys found that, in the absence of stress, chronic lofexidine treatment produced a leftward shift in the cocaine self-administration dose-response curve; accordingly, the authors suggested α2 agonist maintenance may not be generally useful for cocaine use disorder ([@bib191]). In opioid-dependent humans, where YOH produced anxiety and opioid withdrawal-like effects ([@bib141]; [@bib280]; [@bib377]), α2 agonists suppress opioid withdrawal symptoms ([@bib134]) and stress-induced craving ([@bib173]; [@bib361]; but see [@bib268]). Although maintenance on clonidine (vs. placebo) significantly lengthened duration of opioid abstinence among methadone-maintained patients, survival curve analysis revealed no significant clonidine vs. placebo group difference in time to opioid relapse, suggesting circumscribed efficacy ([@bib197]). Some data suggest α-2A receptors primarily mediate anti-stress therapeutic effects of α2 agonists (e.g., guanfacine is a α-2A-specific partial agonist), whereas uncertainty remains regarding the roles of α-2B and α-2C subtypes, as well as whether these effects occur via pre-synaptic autoreceptors or heteromers with non-NA neurons such as glutamate ([@bib355]).

α1 antagonists have been investigated for efficacy in alcohol use disorder, with mixed results. In a recent, placebo-controlled, phase 2 trial, six-week treatment with prazosin (up to 16 mg/day) did not exhibit overall efficacy ([@bib428]). Interestingly, pretreatment blood pressure -- possibly reflecting chronic stress levels -- has been found to moderate the efficacy of prazosin and doxazosin in reducing alcohol intake in two clinical trials ([@bib153]; [@bib428]), such that these medications reduced alcohol intake to a greater degree among patients with higher pretreatment blood pressure.

This review emphasizes a system biology approach to the influence of stress on substance use. Notably, the NA system has been the most extensively studied on its own and interacting with other neurochemical systems. Accordingly, [Table 3](#tbl3){ref-type="table"} summarizes studies that have experimentally analyzed effects of manipulating NA signaling in combination with other systems, specifically for an effect on stress-related substance use. This table is intended to advance the idea that multi-modal medication (polypharmacy or "cocktail") approaches may be useful, and perhaps preferable (i.e., safer and more effective than unimodal intervention), for treating stress-related substance use. [Table 3](#tbl3){ref-type="table"} also illustrates the current research landscape: alcohol and cocaine have most often been studied using this systems biology approach, but there are substantial research gaps for other abused drugs. From a clinical perspective, it is notable that the use of other (non-NA) medications in combination with NA agents might minimize incidence of hypotension (i.e., produce a dose-sparing effect for the NA medication), which is the primary side effect of the NA medication class. Finally, prescribing NA medications for substance abusers who have hypertension could help treat this common comorbid condition.Table 3Studies investigating potential interactions between noradrenergic and other neurochemical systems in stress-related substance use.Table 3Neurochemical SystemNicotineAlcoholCocaineOpioidCRF-1[@bib20]; [@bib210]; [@bib243][@bib50], [@bib49]; [@bib260],[a](#tbl3fna){ref-type="table-fn"}CORT[@bib34]; [@bib358][@bib142][b](#tbl3fnb){ref-type="table-fn"}Orexin-1[@bib305]; [@bib185][@bib43]; [@bib331]5-HT[@bib212][@bib209],[a](#tbl3fna){ref-type="table-fn"}Kappa-opioid[@bib145]; Nygard et al., 2016[@bib122][@bib11][a](#tbl3fna){ref-type="table-fn"}; [@bib398][@bib449]Delta-opioid[@bib277]Nociceptin[@bib314]eCB[@bib150][@bib78][@bib406]GABA-B[@bib430]GABA-A[@bib86]α3β4 nAChR[@bib77]; [@bib440]PPAR-γ[@bib379], [@bib378][@bib87]Neurokinin-1[@bib324][@bib324]Neuropeptide S[@bib332]Neuropeptide Y[@bib79][^6][^7]

For proof-of-target studies, PET radiotracers exist for measuring occupancy of α2C receptors (\[^11^C\]-ORM-13070; [@bib16]) and noradrenaline transporter (\[^11^C\]-MENET; [@bib456]), but none are available for α1-or β-adrenergic receptors.

2.2. HPA axis {#sec2.2}
-------------

### 2.2.1. Corticotropin-releasing factor (CRF) {#sec2.2.1}

As noted in section [1.3](#sec1.3){ref-type="sec"}, infusion of CRF (which mimics supra-physiologic endogenous release from the hypothalamus) reinstates previously extinguished drug seeking in animal models. Notably, CRF-1 receptor knockout animals are less sensitive to stress-induced cocaine seeking ([@bib72]). Thus, CRF-1 antagonists have been explored for blocking stress-induced reinstatement. Early studies found that ICV infusion of non-selective CRF-1/2 receptor antagonists decreased footshock reinstatement of responding for heroin ([@bib343]), cocaine ([@bib105]), alcohol ([@bib218]; [@bib231]) and nicotine ([@bib451]). As summarized in [Table 2](#tbl2){ref-type="table"}, selective CRF-1 antagonism attenuated stress-reinstatement of responding for nicotine, alcohol, cocaine and heroin.

Although these preclinical studies suggest CRF-1 antagonism might be a useful approach for reducing stress-induced drug seeking, this apparent promise must be tempered by contradictory results from recent clinical studies. Two CRF-1 antagonists, pexacerfont and verucerfont, failed to demonstrate anti-craving effects in patients with alcohol use disorder ([@bib207]; [@bib336]). A third CRF-1 antagonist, GSK561679, failed to show anxiolytic effects in a human laboratory model ([@bib146]) and lacked efficacy in a clinical trial with posttraumatic stress disorder patients ([@bib96]). Given this lack of translational efficacy, considerable caution is warranted for similar congeners in this pharmacological class. Several methodological factors could have led to poor translation ([@bib292]; [@bib340]); if these are properly addressed, there could still be a path forward for these agents but, in all likelihood, therapeutic application may be narrower than originally hoped ([@bib374]). Alternative study designs may be needed that measure not only direct effects of the medication on substance use, but also intermediate stress-related phenotypes, e.g., coping or resilience ([@bib83]). One potential moderating factor is that some clinical studies were conducted exclusively with female volunteers, which could influence the generalizability of findings.

Contribution of CRF-2 receptors to stress-induced drug seeking is unclear, due to mixed methods and findings in the literature ([@bib37]; [@bib53]; [@bib420]; [@bib452]). CRF-2 receptors mediate anxiolysis ([@bib25]; [@bib190]; [@bib308]), suggesting CRF-2 agonists (not antagonists) are more appropriate anti-stress medication candidates but, presently, there are no published studies on this topic. Currently, there are no viable CRF-1 or CRF-2 receptor PET ligands for use in studies.

[@bib50] found that ICV infusion of NA reinstated cocaine seeking, which was blocked by pretreatment with the non-selective CRF antagonist D-Phe CRF~12-41~. In contrast, ICV CRF reinstated cocaine seeking but this was not blocked by clonidine pretreatment. Pretreating with the CRF antagonist or clonidine failed to block YOH-induced reinstatement. These findings suggest a functional interaction between NA and CRF systems in mediating stress-reinstatement of cocaine seeking, such that CRF receptor activation occurs downstream from NA sites of action (i.e., at extra-hypothalamic sites, independent of the HPA axis).

[@bib260] demonstrated that reinstatement of cocaine CPP using forced swim or systemic injection of the β2-receptor agonist clenbuterol was blocked by antalarmin or the β2-antagonist ICI-118,551; whereas clenbuterol reinstatement of cocaine CPP was only blocked by antalarmin but not the β2-antagonist. The authors hypothesized that stress-induced liberation of NA activates, via β2 receptors, CRF neurons that lead to drug-motivated responding.

### 2.2.2. Glucocorticoids {#sec2.2.2}

Several early studies demonstrated that footshock stress, while increasing corticosterone (CORT) levels in rats, did not reinstate responding for heroin ([@bib343]), cocaine ([@bib105]), or alcohol ([@bib218]). Although acute pretreatment with the corticosteroid synthesis inhibitor, metyrapone, itself reinstated heroin-seeking behavior, neither acute nor chronic metyrapone exposure, nor adrenalectomy, attenuated footshock-reinstatement of heroin seeking ([@bib343]). These data implied that CORT does not specifically mediate reinstatement. Although one study found that acute pretreatment with the corticosteroid synthesis inhibitor, ketoconazole, blocked footshock reinstatement of cocaine seeking ([@bib241]), ketoconazole has other pharmacological actions, making it unclear whether this effect was HPA axis-specific. Furthermore, sustained ketoconazole treatment in a clinical study led to increased use of cocaine and heroin among methadone-maintained patients ([@bib195]).

Despite the important role of the HPA axis in addiction ([@bib130]), preclinical studies have found that glucocorticoid manipulations, rather than directly influencing drug seeking (given the negative findings above), may instead sensitize the animal to respond more in the presence of drug-related stimuli. [@bib137] found that exposing rats to footshock failed to reinstate cocaine seeking, but footshock did facilitate reinstatement to a subthreshold cocaine priming dose. Further, CORT administered to adrenalectomized rats also reinstated cocaine seeking with a subthreshold cocaine priming dose. Interestingly, CORT infused into the nucleus accumbens (NAc) was found to decrease DA clearance, suggesting CORT potentiation of NAc DA signaling may partly underlie stress-induced reinstatement. This research group also found that acute CORT alone did not reinstate extinguished cocaine CPP ([@bib259]) or self-administration ([@bib257]); however, CORT enhanced efficacy of a sub-threshold cocaine priming dose to reinstate cocaine CPP and self-administration ([@bib257], [@bib259]); thus, the stressor (CORT) "set the stage" for acute cocaine exposure to reinvigorate drug- or drug-paired responding. Also, these investigators found CORT and footshock-stress effects on cocaine-primed reinstatement of self-administration that were mediated by eCB signaling via CB~1~ receptors and the enzyme monoacylglycerol ([@bib258], [@bib257]). This research illustrates an interaction between the HPA axis and eCB system in the control of stress-occasioned relapse-like behaviors and suggests a role for using eCB modulators to attenuate the direct and indirect effects of stressors on drug-maintained behaviors (see section [2.6](#sec2.6){ref-type="sec"}).

Given the complexities of the HPA axis (e.g., negative feedback loops within the HPA axis; see [Fig. 2](#fig2){ref-type="fig"}), and the findings above that adrenalectomy or inhibition of corticosteroid synthesis did not block drug seeking, the potential utility of glucocorticoid receptor (GR) antagonists as anti-stress therapeutics must be seriously questioned. Also, nicotine abstinence is associated with HPA axis hypo-sensitivity ([@bib5]; [@bib339]), so it is unclear whether GR antagonists would be useful. On the other hand, a recent study found that the dual GR/progesterone antagonist mifepristone and the GR-specific antagonist CORT113176 each dose-dependently reduced escalated alcohol intake in rats and, in a companion clinical study, maintenance on mifepristone 600 mg/day (vs. placebo) reduced alcohol drinking among individuals with alcohol use disorder ([@bib407]). Further investigation of these agents is warranted to shed light on the specific mechanisms through which this effect may occur, and whether it may be unique to alcohol or apply to other abused drugs.Fig. 2Systems Biology: Illustration of major neurochemical pathways that integrate and underlie stress-potentiated drug-seeking/use behaviors. See text for discussion of some of these inter-connections, as well as [Table 3](#tbl3){ref-type="table"} relating NA function to other neurochemical systems.Fig. 2

Consistent with the systems biology focus in this review, NA and glucocorticoid systems produce co-operative effects in multiple paradigms ([@bib97]; [@bib117]; [@bib192]; [@bib334], [@bib335]; [@bib393]; [@bib399]; [@bib403]; [@bib404]). This prompted our recent study to co-activate these systems using separate and combined challenges with YOH and hydrocortisone (synthetic CORT) ([@bib142]). In a within-subject randomized crossover design, heroin-dependent buprenorphine-maintained volunteers were pretreated with oral YOH (0-, 27- and 54-mg) and CORT (0-, 20- and 40-mg) alone and combined. YOH/CORT increased opioid (hydromorphone) choices, relative to placebo pretreatment, while reducing money choices (i.e., stress increased opioid preference) but this effect was modulated by individual\'s pre-experimental variation in daily nicotine use. This pharmacological stress model was recently applied to cigarette smokers. Relative to placebo, YOH-54mg/CORT-10mg pretreatment induced similar physiological stress responses as above. Controlling for nicotine-dependence level, acute stress increased nicotine seeking ([@bib436]).

2.3. Serotonin system {#sec2.3}
---------------------

Several studies implicate 5-HT neurotransmission in stress-induced reinstatement of alcohol seeking (whereas similar studies with abused drugs are lacking). In an initial study, alcohol seeking was reinstated by footshock and reversed by the 5-HT reuptake inhibitor fluoxetine ([@bib219]). Subsequently, the 5-HT-1A agonist 8-OH-DPAT (which decreases 5-HT cell firing and transmitter release) infused in the median raphe nucleus (MRN) reinstated alcohol seeking; furthermore, intra-MRN infusion of CRF reinstated alcohol seeking ([@bib216]). In a follow-up study, CRF antagonist infusion in the MRN attenuated YOH-reinstatement of alcohol seeking ([@bib210]). Together, these findings point to 5-HT/CRF interaction within the MRN as mediating this stress effect. In addition to its primary α2-antagonist action, YOH also acts as a 5HT-1A partial agonist, which could partly explain its stress-reinstating efficacy. Furthermore, intra-MRN infusion of muscimol (GABA-A receptor agonist) reinstated alcohol seeking, implicating a 5-HT/GABA-A interaction in the MRN ([@bib214]).

The 5-HT~3~ receptor antagonists, ondansetron and tropisetron (FDA-approved for treating nausea and vomiting), have been demonstrated to attenuate footshock-reinstatement of alcohol seeking in rats ([@bib213]). However, these anti-stress effects have not yet been explored for other abused substances.

In summary, limited data suggest agents that promote 5-HT release, prevent reuptake, or block 5-HT-3 receptors could be useful therapeutics, although such effects may depend on raphe-mediated interactions; thus, systemic delivery could produce mixed effects. Given widespread clinical use of SSRIs and 5-HT-3 antagonists, systematic research across classes of abused drugs is warranted. Target-selective PET tracers are available that measure 5-HT transporter occupancy using \[^11^C\]DASB (for review, [@bib375]); 5-HT synthesis using α-\[^11^C\]-methyl-L-tryptophan ([@bib201]); and 5-HT1A receptor binding using \[*carbonyl*-^11^C\]-WAY100635 or possibly \[^11^C\]-CUMI-101, but none for 5-HT-3 receptors (for review, [@bib202]).

2.4. Opioid system {#sec2.4}
------------------

Although the non-selective opioid receptor antagonist naltrexone (NTX) is used to treat alcohol and opioid use disorders, NTX does not block stress-induced alcohol or opioid use (e.g., [@bib167]; [@bib219]). Notably, NTX can increase YOH reactivity ([@bib315]), and a clinical trial found that adding the α2-agonist guanfacine to NTX did not improve opioid abstinence over NTX alone ([@bib200]).

It is presently unclear whether opioid agonist medications might (in addition to their withdrawal-suppressing and opioid blockade properties; see [@bib140]) attenuate stress-reactivity among individuals with opioid use disorder. One animal study found that maintenance on the *mu*-agonist methadone (MTD) did not block stress-reinstatement of heroin seeking ([@bib225]). Results from cross-sectional clinical studies suggest MTD might blunt stress-reactivity ([@bib178]; [@bib198]; [@bib329], [@bib330]) but those studies have methodological flaws, e.g., variable maintenance doses, potential pre-morbid differences between patients and controls, and failure to match controls on other substance use. Buprenorphine (BUP) is a partial *mu*-receptor agonist/*kappa*-receptor antagonist with rapid-onset antidepressant and anxiolytic effects in animal models ([@bib108]) and human studies ([@bib33]; [@bib40]; [@bib183]; [@bib279]). In the clinical dosing range for opioid use disorder, BUP may be stress-protective *via* one or both of these mechanisms; our lab is presently investigating this issue.

### 2.4.1. Kappa-opioid receptor (KOR) antagonists {#sec2.4.1}

Stressors have been shown to release dynorphin and activate *KOR*s located on DA and 5-HT neurons, thereby reducing DA and 5-HT levels ([@bib63]; [@bib98]; [@bib127]; [@bib208]; [@bib444]) that, in turn, are associated with negative-hedonic effects of stressors ([Fig. 1](#fig1){ref-type="fig"}). Furthermore, *KOR* agonist administration reliably reinstates responding for cocaine (see [Table 1](#tbl1){ref-type="table"}).

Accordingly, *KOR* antagonists are being evaluated as potential anti-depressants ([@bib64]; [@bib114]; [@bib147]; [@bib444]) and anti-stress/drug-relapse prevention agents. As summarized in [Table 2](#tbl2){ref-type="table"}, *KOR* antagonists reliably attenuate stress-reinstated responding for nicotine, alcohol (but see [@bib322]), cocaine, and heroin. Although no tests of *KOR* antagonism of stress-related substance abuse have been conducted in humans to date, PET ligands for measuring *KOR* occupancy are available including \[^11^C\]-LY2795050 ([@bib271]) and \[^18^F\]-LY2459989 ([@bib227]).

Evidence also suggests dynorphin projections to NA and GABA neurons in the locus coeruleus ([@bib199]; [@bib302]) modulate stress-related drug reinforcement. Studies in rats have identified *KOR*/noradrenergic interactions in the locus coeruleus that mediated reinstatement of cocaine lever-responding ([@bib11]), and *KOR*/serotonergic projections from the dorsal raphe to the NAc that mediated reinstatement of cocaine conditioned place preference (CPP) ([@bib209]). Finally, interactions between dynorphin/*KOR*s and CRF have been proposed as one mechanism by which stressors lead to changes in allostatic load, altering the motivational valence of the abused substance ([@bib51]; [@bib194]).

### 2.4.2. Delta-opioid receptor (DOR) compounds {#sec2.4.2}

*DOR*s are a potential anti-stress target, given their established role in anxiety-like behaviors in animal models; however, their pharmacology is incompletely understood, including differing functions of *DOR* subtypes, stress-induced translocation of *DOR*s from cytoplasm to cell surface, and potential for *DOR*s to form heteromers with *mu*-receptors ([@bib402]). In the only relevant study to date, YOH-reinstatement of alcohol seeking was attenuated by a *DOR-1* antagonist, SoRI-9409 ([@bib277]). Further research with *DOR* subtype-specific agonist and antagonists is needed to determine whether such agents could be useful anti-stress therapeutics. The PET ligand \[^11^C\]methyl-naltrindole is clinically available ([@bib236]; [@bib363]) and has been used to measure *DOR* binding potential in alcohol-dependent individuals ([@bib418]; [@bib425], [@bib426]).

2.5. Nociceptin receptor (NOP) compounds {#sec2.5}
----------------------------------------

Although the NOP system is involved in stress-reactivity and addictive behaviors, historically less clear is whether NOP agonists or antagonists should be effective anti-stress agents. On the one hand, NOP agonists have shown therapeutic promise against stress-reinstatement of alcohol seeking. Footshock-reinstatement of alcohol seeking was attenuated by ICV administration of nociceptin ([@bib245]) and systemic administration of the non-peptide, brain-penetrant NOP agonist MT-7716 in post-dependent rats but not alcohol-naïve rats ([@bib88]). The latter findings suggest a history of alcohol dependence dysregulates the nociceptin system, which can be reversed with NOP agonist treatment. A different small-molecule NOP agonist, SR-8993, blocked YOH-reinstatement of alcohol seeking ([@bib21]). Conversely, other studies have found that NOP antagonists and NOP knockout mice produce anti-obesity and anti-depressant effects (review by [@bib435]), and the orally bioavailable, brain-penetrant, NOP antagonist LY2940094 blocked YOH-reinstatement of alcohol seeking in alcohol-preferring rats ([@bib314]).

[@bib435] proposed a hypothesis to reconcile these differences; specifically, nociceptin serves as part of a stress-coping negative-feedback mechanism, eliciting a stress-like response within the HPA axis but anti-stress effects at extra-hypothalamic sites. For future studies, the PET ligand \[^11^C\]NOP-1A ([@bib232]) is available to measure NOP binding potential in human subjects ([@bib274]).

2.6. Endocannabinoid (eCB) system {#sec2.6}
---------------------------------

Initial studies of the eCB system as an anti-stress target focused on CB~1~ receptor antagonists. Administration of the CB~1~ antagonist rimonabant to rats failed to attenuate footshock-reinstatement of alcohol seeking ([@bib99]; [@bib100]) and cocaine seeking ([@bib90]). Moreover, side effects of rimonabant in clinical trials led to discontinuation of its therapeutic development. The neutral CB~1~ antagonist AM4113 dose-dependently reduced YOH-reinstatement of nicotine seeking without altering inactive-lever or food-maintained responding acutely, although chronic treatment led to weight loss ([@bib150]). In contrast, the CB~1~ antagonist AM251 blocked forced swim-induced cocaine reinstatement ([@bib405]) and AM251 blocked CRF- but not footshock-reinstatement of cocaine seeking ([@bib203]). Given these mixed effects of CB~1~ antagonists on stress-reinstatement, it is unclear whether findings may depend on interactions between the CB~1~ antagonist, stressor, and abused substance.

An alternative strategy is to modulate signaling indirectly within the eCB system. One promising approach is to promote eCB transmission by facilitating actions of the endogenous ligand anandamide (AEA). Although acute administration of the FAAH inhibitor URB597 (which increases AEA levels by inhibiting its catabolism) did not attenuate footshock- or YOH-reinstatement of alcohol seeking ([@bib78]), [@bib71] argued that chronic administration of anti-stress medication is a preferable model, because (1) this directly pertains to the human condition, (2) chronic exposure controls for possible tolerance development, and (3) medication-induced neuroadaptations may be required for a therapeutic effect. Using this approach, they demonstrated that URB597 significantly attenuated YOH-reinstatement of cocaine seeking ([@bib71]). Targeting fatty acid binding proteins, which transport AEA intracellularly to FAAH for degradation, is a related strategy to interfere with stress-induced drug seeking ([@bib154]).

The eCB cannabidiol (CBD) has diverse neuropharmacological actions but salient among these includes enhancing AEA levels with weak antagonist actions at CB~1~ and CB~2~ receptors ([@bib60]; [@bib170]; [@bib186]; [@bib256]; [@bib263]; [@bib286]; [@bib287]; [@bib317]; [@bib391]). Transdermal CBD administration was recently found to attenuate acute and repeated YOH-reinstatement of cocaine and alcohol seeking and produced anxiolytic and anti-impulsive effects without disrupting other reward behavior or locomotion, and this profile of effects endured long after CBD was biologically detectable ([@bib133]). Further studies are needed, but CBD represents a novel anti-stress therapeutic approach.

PET radiotracers are clinically available that measure binding potential in the eCB system including \[^11^C\]-CURB ([@bib41]; [@bib316]) and \[^11^C\]-MK3168 ([@bib293]) for FAAH; \[^11^C\]-OMAR ([@bib278]) and \[^11^C\]-MePPEP and \[^18^F\]-FMPEP-d ([@bib389]) for CB~1~ receptors; and \[^11^C\]-NE40 for CB~2~ receptors ([@bib2]). Measurement of eCB levels in biological matrices is promising and undergoing refinement ([@bib93]; [@bib112]; [@bib405]; [@bib417]; [@bib434]).

2.7. Orexin system {#sec2.7}
------------------

Orexin fibers (originating mostly in the lateral hypothalamus) project widely in the brain, including to VTA, NAc and extended amygdala and, thus, are well-positioned to influence motivated behavior. The orexin system has been demonstrated to influence stress-induced seeking for several abused substances. ICV administration of orexin-1 but not orexin-2 peptide reinstates drug seeking ([@bib43]; [@bib157]; [@bib290]; [@bib421]), consistent with a broader role for orexin-1 in compulsive behavior ([@bib288]). Notably, the orexin-1 receptor-selective antagonist SB-334867 dose-dependently reduced footshock- and YOH-reinstatement of cocaine responding, particularly in rats given long-access to cocaine, a model of escalated drug use ([@bib43]; [@bib331]; [@bib421]). A set of studies found that restraint stress initially activated hypothalamic orexin neurons to release orexins into the VTA, activating postsynaptic VTA DA neurons, causing retrograde eCB inhibition of GABA release, leading to VTA DA disinhibition that resulted in reinstatement of cocaine CPP ([@bib394]).

Systemic pretreatment with SB-334867 attenuated YOH-reinstatement of alcohol seeking, without altering locomotion ([@bib305]). However, a later study found that only micro-injection of an orexin-2 receptor antagonist (but not SB-334867) into the pontine *nucleus incertus* attenuated YOH-reinstatement of alcohol seeking ([@bib185]). These mixed results could be due to different methods. A human study found that plasma concentrations of orexin -- which may reflect diffusion of the peptide between CNS and peripheral compartments ([@bib184]) -- during alcohol abstinence positively correlated with psychological distress levels ([@bib412]); thus, it is plausible that orexin modulates stress- or abstinence-related alcohol use. However, there are also contrary data in cigarette smokers, showing a negative relationship between peripheral orexin-1 levels and nicotine craving ([@bib411]).

For nicotine, SB-334867 blocked reinstating effects of ICV orexin and footshock on nicotine seeking; in contrast, SB-334867 did not block CRF-induced nicotine reinstatement, and the CRF-1 antagonist antalarmin did not block ICV orexin-induced nicotine reinstatement, indicating autonomous control of stress-related drug-seeking across these two systems ([@bib290]).

For opioids, pretreatment with either orexin-1 or orexin-2 receptor antagonists in the NAc shell (which processes positive and negative affectively-valenced behaviors) attenuated reinstatement of morphine CPP ([@bib294]).

Suvorexant is a non-selective orexin-1/2 receptor antagonist approved for treating insomnia. Evidence indicates that orexin-2 antagonism is responsible for the sleep-inducing effect ([@bib12]). Consistent with findings above, orexin-1 antagonists such as GSK1059865 ([@bib135]) are being developed as anti-stress and anti-addiction pharmacological tools, although none are clinically available at this time. Although there are emerging orexin-2 ligands for PET imaging such as \[^11^C\]-MK-1064 ([@bib125]) and \[^11^C\]-CW4 ([@bib422]), at this time there are no viable orexin-1 radiotracers.

2.8. Glutamatergic system {#sec2.8}
-------------------------

Multiple signals converge on glutamate signaling to alter stress-induced drug seeking. The effect of footshock stress on cocaine responding was shown to depend on glutamate via dorsal PFC/NAc core interaction ([@bib454]) and VTA CRF signaling ([@bib419]; [@bib429]), ultimately leading to increase NAc DA transmission ([@bib433]). Cold-water forced-swim stress was shown to alter AMPA/NMDA receptor ratio in the NAc shell, an effect that was reversed with the glucocorticoid receptor antagonist RU486 ([@bib453]). NA signaling through α2 and β2 receptors in the dorsal BNST, can bidirectionally modulate glutamate transmission ([@bib102]). Although these examples are not exhaustive, they illustrate that glutamate signaling in stress-related behavior is mostly secondary to other systems. This implies that a direct pharmacological approach to modulating glutamate function may be challenging for treating stress-related substance use.

Two agents with glutamate transmission-dampening properties, a mGluR2/3 agonist (LY379268) and mGluR5 antagonist (MTEP), each dose-dependently reduced footshock-reinstatement of cocaine seeking ([@bib246]) and alcohol seeking ([@bib356]; [@bib445]). These findings suggest mGluR2/3 and mGluR5 targets (primarily located in pre-/peri- and post-synaptic spaces, respectively) should be studied further, given the established anxiolytic effects of LY379268 and MTEP in animal models (e.g., [@bib188]).

On the other hand, a review of medications for treating cocaine addiction (not specific to stress-induced drug seeking) suggested that allosteric modulators could be pursued ([@bib179]). Given the evidence above, reasonable candidates to be considered would be positive allosteric modulators of mGluR2/3 receptors and negative allosteric modulators of mGluR5 receptors. Given similar neuroadaptations from chronic alcohol (relative to cocaine) use, including a hypersensitive glutamate system ([@bib408]), it may be fruitful to investigate these allosteric modulators for stress-induced alcohol use. Yet, an initial test of this hypothesis found that the mGluR2-selective positive allosteric modulator AZD8529 attenuated cue- but not footshock-reinstatement of alcohol seeking in rats ([@bib19]). Those authors note that this difference in findings across studies could imply that mGluR3 rather than mGluR2 receptors are distinctly involved in stress-related drug responding, or that orthosteric agonists and positive allosteric modulators could modulate glutamate function in distinct ways.

Several biomarkers are available to measure glutamate function in human subjects. Emerging PET radiotracers for measurement of brain glutamate targets include \[^18^F\]-FIMX for mGluR1 receptors ([@bib443]), and \[^11^C\]-ABP688 ([@bib177]) and \[^18^F\]-FPEB ([@bib384]) for mGluR5 receptors. High-field proton magnetic resonance spectroscopy (^1^H-MRS) has proved sensitive to pharmacotherapy-related repeated-measures change in brain-regional glutamate concentrations in substance abusers ([@bib143]; [@bib396]).

2.9. GABAergic system {#sec2.9}
---------------------

The GABA-A agonist muscimol, when injected into the median raphe nucleus, reinstated alcohol seeking ([@bib214]). However, intra-VTA modulation of GABA-A receptors using the GABA-A antagonist bicuculline did not block footshock- or intra-VTA CRF-induced reinstatement of cocaine seeking ([@bib38]). However, it is possible that a GABA-A positive allosteric modulator could offer a useful alternative; one such compound is in development ([@bib244]).

In contrast, the GABA-B agonist baclofen was found to block YOH-induced alcohol seeking ([@bib430]) and to attenuate forced swim stress-reinstatement of morphine CPP ([@bib261]). However, these encouraging results must be reconciled with conflicting findings that intra-VTA infusion of a GABA-B antagonist, 2-hydroxysaclofen, blocked reinstatement of cocaine seeking by footshock and intra-VTA CRF administration ([@bib38]). Thus, it is unclear whether using a GABA-B agonist or antagonist would be preferable against stress-induced drug seeking, or whether this might vary by the abused substance or route of delivery.

GABA modulation with pregabalin (a clinically available medication) was found to block YOH-reinstatement of alcohol seeking ([@bib380]) and cocaine seeking ([@bib86]). The GAT-1 inhibitor tiagabine has been demonstrated to reduce anxiety- and depressive-like behaviors in animal models ([@bib390]) but has not yet been tested in experimental models of stress-induced drug seeking/use.

Biomarkers for GABA system targets include the PET radiotracer \[^11^C\]-flumazenil for GABA-A receptors ([@bib176]; [@bib229]), and ^1^H MRS imaging for cortical GABA concentrations ([@bib247]; [@bib382]).

2.10. Other candidates {#sec2.10}
----------------------

For completeness of coverage, this section briefly notes promising alternative candidates with relatively less empirical evidence.

### 2.10.1. Neuropeptides {#sec2.10.1}

Oxytocin is synthesized in the hypothalamus and binds to oxytocin and vasopressin receptors in brain regions implicated in regulating stress-reactivity, emotional and social behaviors ([@bib160]; [@bib276]; [@bib431]). Studies of oxytocin suggest its clinical potential for several psychiatric conditions ([@bib187]; [@bib262]; [@bib272]; [@bib295]) although some therapeutic effects are likely to be sex-dependent ([@bib36]). Overall, few studies relate to substance abuse, and oxytocin might have greater promise for treating stress-related psychiatric conditions comorbid with SUDs ([@bib441]). An oxytocin analogue, carbetocin, attenuated forced-swim stress-reinstatement of morphine CPP, while attenuating stress-induced plasma CORT response ([@bib442]). Amygdala arginine vasopressin (AVP)1b receptors have been implicated in footshock-reinstatement of heroin seeking ([@bib447], [@bib448]), suggesting V1b receptor antagonism might be a viable target for blocking stress-related relapse. One V1b antagonist (ABT-436) is in clinical trials for treatment of alcohol use disorder ([@bib318]).

Neuropeptide S (NPS) acts at the NPS receptor to increase arousal and locomotion while decreasing anxiety-like behavior ([@bib223]; [@bib309]; [@bib437]). This paradoxical profile -- anxiolysis but increased locomotion (often associated with reinforcing effects) -- resembles that of nicotine, creating uncertainty as to whether agonists or antagonists of this system would be optimal anti-stress candidates. [@bib332] adopted an NPS receptor antagonist approach, based on the idea that NPS may promote addictive behaviors. Using RTI-118, they found it decreased YOH- as well as cue- and cocaine priming-induced reinstatement of cocaine seeking, indicating a broad efficacy profile ([@bib332]). NPS receptors are co-localized with other hypothalamic-originating neuropeptides discussed in this review, including orexin and CRF receptors. Hypothalamic NPS infusion has been shown to reinstate alcohol and cocaine seeking, effects that are reversed by the orexin-1 antagonist SB-334867 ([@bib61]; [@bib180]; [@bib395]) and the CRF-1 antagonist antalarmin ([@bib281]).

Neuropeptide Y binds multiple receptor subtypes; however, most studies have investigated Y1 (mostly postsynaptic) and Y2 (mostly presynaptic) receptors with the latter negatively modulating NPY release ([@bib81]; [@bib107]; [@bib189]) to produce numerous biobehavioral effects including anxiolysis ([@bib159]). The actions of NPY counteract CRF-induced anxiogenesis ([@bib158]; [@bib320]; [@bib397]). Central NPY infusion blocked YOH-reinstatement of alcohol seeking ([@bib79]). Systemic pretreatment with the Y2-selective antagonist, JNJ-31020028, failed to block footshock-reinstatement of alcohol responding ([@bib80]). A similar stress-reinstatement blocking test has not been reported for a Y1-selective agonist. Experimental results from studies of this system could be complicated by findings that Y1 and Y2 receptors (which have opposite functions regarding anxiety-like behavior) can form homo- and hetero-dimers whose net effect might negate the effects of receptor-selective stimulation ([@bib92]; [@bib357]).

Substance P is a tachykinin-family neuropeptide selective for the neurokinin-1 (NK-1) receptor. The NK-1 receptor antagonist aprepitant is FDA-approved for treating chemotherapy-induced nausea and biosimilars are in the pipeline. Clinical development of NK-1 antagonists has met with difficulties perhaps, not surprisingly, because these agents share functional features with CRF-1 antagonists that have associated negative findings (see section [2.2.1](#sec2.2.1){ref-type="sec"}; [@bib323]). Preclinical studies have shown that the NK-1 antagonist L822429 blocks YOH- or footshock-reinstatement of alcohol and cocaine seeking ([@bib326], [@bib324], [@bib325]). Although a phase 2 clinical study found that the NK-1 antagonist LY686017 decreased spontaneous and psychological stress-induced alcohol craving and cortisol responses in high trait-anxious, alcohol-dependent volunteers ([@bib128]), a subsequent placebo-controlled study of aprepitant administered to alcohol-dependent patients with co-occurring PTSD failed to replicate these findings ([@bib206]). Although it remains unclear whether NK-1 antagonists could reduce acute stress-induced effects among individuals who are not highly anxious, this would considerably restrict the clinical utility of this class of medication. The PET ligand \[11C\]-GR205171 is available for measuring NK-1 binding potential in humans ([@bib121]; [@bib306]; [@bib376]).

Relaxin-3 is a peptide acting at its cognate receptor RXFP3 and, similar to orexin, relaxin-3 agonists increase stress-reactivity, food intake and arousal. In contrast, relaxin-3 antagonism, at least partly mediated via the BNST, blocked YOH-reinstatement of alcohol- but not sucrose-seeking ([@bib319]); furthermore, RXFP3 deletion blocked physical (repeated restraint followed by swim) stress-reinstatement of alcohol seeking without disrupting baseline alcohol or saccharin intake, or hepatic metabolism of alcohol ([@bib416]). Thus, relaxin-3 antagonists may be reasonable anti-stress agents, although efficacy with other abused drugs has not been tested to date.

### 2.10.2. Non-peptides {#sec2.10.2}

FDA-approved nicotine replacement treatments (NRTs) do not attenuate stress-induced drug seeking or use ([@bib196]; [@bib298]). Interestingly, the α3β4 nAChR partial agonist AT-1001 dose-dependently attenuated YOH-reinstatement of nicotine seeking ([@bib440]). Furthermore, AT-1001 selectively blocked YOH- but not cue-reinstatement of alcohol seeking without affecting baseline alcohol or food intake ([@bib77]). This novel approach could potentially address some limitation of current NRTs and assist the many individuals who concurrently use tobacco and alcohol.

Pioglitazone, agonist at the peroxisome proliferator-activated receptor-gamma (PPARγ) subtype, was shown to attenuate YOH-reinstatement of alcohol seeking ([@bib379], [@bib378]) and heroin seeking ([@bib87]).

3. Discussion {#sec3}
=============

The development of anti-stress medications is critical for the advancement of treating all SUDs. The impact of stressors extends across abused substances (which contrasts with the effects of drug-priming and drug-cue exposure, which tend to be specific to drug classes). Therefore, progress in this field has significant potential to apply scientifically across all drug classes and to improve treatment of all patients with SUDs. This review describes available evidence on promising neuropharmacological approaches, using mechanistic studies based on chemical and non-chemical probes ([Table 1](#tbl1){ref-type="table"}). Although studies of Δ^9^-THC/marijuana were surveyed for this review, there is a paucity of studies in this area.

Based on the quality of evidence to date, promising first-tier neurochemical targets include: NA (α1-and β-antagonist, α2 agonist), *kappa*-opioid antagonist, NOP antagonist, orexin-1 antagonist, and eCB modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include CRF-1 antagonists, serotonergic agents (reuptake inhibitors, 5-HT-3 antagonists), glutamatergic agents (mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-signaling promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). DA antagonists were excluded from this review because, although brain site-specific studies in animals support a role for DA in mediating stress-induced drug seeking ([@bib454]), when DA antagonists are administered systemically (and especially chronically) they produce side effects that do not translate well into clinical practice.

[Table 2](#tbl2){ref-type="table"} complements this review by adding a layer of theoretical analysis pertaining to affective/motivational mechanisms that may be modulated while intervening in these neurochemical systems. I propose the overarching hypothesis that, to be effective, anti-stress medications for substance use disorders must alleviate the multidimensional burden of stressors that can lead to behavioral deficits including avoidance (valence dimension), hyperactivation (arousal dimension), and impulsivity (control dimension), that can perpetuate substance use and its adverse consequences. [Table 2](#tbl2){ref-type="table"} illustrates that few candidate pharmacotherapeutic approaches are likely to tackle all these problems. Accordingly, to address these affective/motivational mechanisms of stress-related substance use, it seems advisable to combine agents with actions at complementary targets for greater efficacy; however, it should be noted that systematic studies are lacking except for interactions with the NA system ([Table 3](#tbl3){ref-type="table"}). Future research could be directed at whether some agents may function to desensitize subjects from chronic stress-induced effects (e.g., glucocorticoid receptor antagonist), whereas other agents might help to block acute stress-induced effects (e.g., α2 agonist or α1 antagonist). It is plausible that both types of agents together may be more effective than either alone. Some agents may also have additional effects beyond anti-stress, such as to block cue-induced drug seeking (e.g., eCB modulators, orexin-1 antagonist).

A key methodological factor concerns whether medication development studies employ acute vs. chronic administration. Although acute medication administration is the dominant paradigm to date, partly due to its efficiency, [@bib71] effectively argued that chronic exposure is desirable for applied clinical relevance, to avoid false negative results attributable to development of tolerance, and to enable within- and/or between-system neuroadaptations (including epigenetic changes) to occur. Future studies should carefully weigh these issues, e.g., whether to screen medications acutely (but perhaps also chronically) during early-stage development but move to chronic dosing in phase 2 studies.

3.1. Biomarkers {#sec3.1}
---------------

Programmatic studies should include biomarkers of stress-reactivity and medication targeting to confirm mediation of effects on drug-seeking behavior. Section [2](#sec2){ref-type="sec"} mentioned clinically available PET ligands for measuring occupancy of molecular targets and use of ^1^H-MRS for measuring glutamate and GABA brain-regional concentrations. These CNS biomarkers should be paired with measurement of medication plasma concentrations, and target occupation/stimulation and plasma pharmacokinetic data should be correlated with one another and with pharmacodynamic effects (clinical endpoints) to generate exposure-response functions. We successfully applied a similar PK/PD modeling strategy for optimizing sublingual and depot buprenorphine treatment of opioid use disorder ([@bib140]; [@bib457], [@bib275]) and this approach was recently applied in the development of the NOP antagonist LY2940094 ([@bib313], [@bib314]).

3.2. Heterogeneity of effect {#sec3.2}
----------------------------

As indicated in [Table 2](#tbl2){ref-type="table"}, which maps neurobiological and motivational foundations of anti-stress medications, it seems unlikely that any single medication will be highly effective for attenuating stress-mediated negative-hedonic, arousal/activating, and disinhibiting/loss-of-control effects on drug-maintained behaviors. Furthermore, chronic dosing may lead to between-system adaptations resulting in loss of efficacy over time, so it may be advantageous to employ a redundant approach (e.g., use two medications that each target one motivational dimension, but via different pharmacological stimulation). This approach emphasizes using one or more anti-stress medications that exert actions that address multiple motivational features of stress-reactive drug use. Using the model proposed here, a predictable consequence of deploying highly targeted compounds would be restricted efficacy. Individual difference factors need to be considered in the context of medication development; inattention to these variables will also limit efficacy (section [1.4](#sec1.4){ref-type="sec"}).

3.3. Summary {#sec3.3}
------------

This review has identified promising, evidence-based neurochemical mechanisms and potential pharmacotherapeutic leads to combat stress-induced substance seeking/use, a major problem for all SUDs. Medications that prove safe and effective could be added to existing SUD pharmacotherapies (e.g., agonist therapies for opioid or nicotine use disorder) to augment treatment efficacy, as most FDA-approved agonist treatments were not designed as anti-stress agents. To address motivational dimensions of stress-related substance use, it will be theoretically and pragmatically valuable to test agents with complementary actions alone and in combination to improve efficacy. As these agents are developed, it will be important to recognize numerous clinically-relevant factors (some of which could be modeled in animal studies) that could mediate/moderate the efficacy of anti-stress agents. Finally, progress in developing anti-stress medications will also depend on use of reliable CNS biomarkers to validate exposure-response relationships.
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[^1]: CPP paradigm.

[^2]: Clinical study.

[^3]: Based on broad, non-exhaustive assessment of empirical literature (using serial PubMed searches that crossed each CNS target label \[or closely related terms, e.g., "anxiety" instead of "dysphoria", "impulsivity" instead of "disinhibition"\] with each stress-motivational dimension label in this table, as well as studies reviewed herein), the author\'s subjective designation of "+" indicates that the CNS target is *likely involved* in counteracting the stress-induced motivation-dimensional outcome. Designation of "?" indicates *mixed evidence or uncertainty*, and blank cells indicate *minimal or no supporting evidence*. The designation of "--" indicates possible worsening of this motivational feature (particularly with chronic dosing). This global summary is simply intended for guidance in mapping these theoretical dimensions to neurochemical mechanisms and, more importantly, for designing studies to formally test effects of these CNS targets against motivational phenotypes, ultimately moving toward combinations of medications for pan-efficacy (see [Table 3](#tbl3){ref-type="table"}).
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[^5]: Clinical study.

[^6]: CPP paradigm.

[^7]: Clinical study.
